Kintara Therapeutics Inc (KTRA)

NASDAQ
1.8000
0.0000(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.0000/0.0000
  • Day's Range:
    1.7600 - 1.9800

KTRA Overview

Prev. Close
1.81
Day's Range
1.76-1.98
Revenue
-
Open
1.86
52 wk Range
0.8522-3.35
EPS
-2.11
Volume
0
Market Cap
58.71M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
908,931
P/E Ratio
-
Beta
1.54
1-Year Change
79.1%
Shares Outstanding
32,617,939
Next Earnings Date
Nov 15, 2021
What is your sentiment on Kintara Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Kintara Therapeutics Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellStrong SellStrong Sell
Technical IndicatorsBuyBuyStrong SellStrong SellNeutral
SummaryNeutralNeutralStrong SellStrong SellSell

Kintara Therapeutics Inc Company Profile

Kintara Therapeutics Inc Company Profile

Employees
4

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California.

Read More
  • when will go 5$??>
    0
    • Never?
      0
    • Pippo Tornatissi so, 3$ is possible?
      0
  • Go and fly wt me! 3,50 coming
    0
    • Great after
      0
      • Hope this Will break 2 dollars Soon and stay above, going for 3 dollars
        0
        • Very underrated according to webull: https://www.webull.com/quote/nasdaq-ktra
          0
          • Two analysts have recently given KTRA a "buy" rating and price targets of $3 and $6.
            0
            • Two buy ratings now. https://www.smarteranalyst.com/new-blurbs/maxim-group-releases-a-buy-rating-on-kintara-therapeutics-ktra/
              0
              • charts are turning up
                0
                • up
                  0
                  • any news
                    0
                    • Yes
                      0
                      • any news today or just spiking?
                        0
                        • hey man
                          1
                          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.